PCSK9 Inhibitors for Lowering Cholesterol: Ready for Prime Time? - Minneapolis Heart Institute Foundation
PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review | Journal of the American Heart Association
Molecules | Free Full-Text | PCSK9 as a Target for Development of a New Generation of Hypolipidemic Drugs | HTML
PCSK9 Inhibitors: What You Need to Know — tl;dr pharmacy
Frontiers | PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects | Physiology
Can the third PCSK9 drug succeed where the first two failed? - Features - MM+M - Medical Marketing and Media
PCSK9 inhibitors: A new era of lipid lowering therapy
Recent advances in developing PCSK9 inhibitors for lipid-lowering therapy | Future Medicinal Chemistry
Targeting PCSK9: a promising adjuvant strategy in cancer immunotherapy | Signal Transduction and Targeted Therapy
Frontiers | PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects | Physiology
PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes. | Semantic Scholar
Cholesterol-Lowering PCSK9 Inhibitors Near Market Entry
Managed Care Pharmacist Updates for Proprotein Convertase Subtilisin/kexin type 9 (PCSK9) Inhibitors
PCSK9 Inhibitor Use in the Real World: Data From the National Patient‐Centered Research Network | Journal of the American Heart Association
CV benefit of PCSK9 inhibitor is consistent regardless of inflammation level - PACE-CME
Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design - IRBM
PCSK9 and its Inhibitors: A new approach in lipid lowering therapy | BioVendor R&D
The Emerging Role of PCSK9 Inhibitors in Preventive Cardiology | ECR Journal
PCSK9 inhibition as an emerging lipid lowering therapy: Unanswered questions - ScienceDirect
A systematic approach for successful PCSK9 inhibitor prescribing in clinical practice - Journal of Clinical Lipidology
PCSK9 inhibitor mechanism of action
Why Merck's PCSK9 Inhibitors Are a Big Deal - Drug Hunter
A small-molecule inhibitor of PCSK9 transcription ameliorates atherosclerosis through the modulation of FoxO1/3 and HNF1α - eBioMedicine
The Evolving Future of PCSK9 Inhibitors - ScienceDirect
Evolocumab becomes first PCSK9 inhibitor to be approved to prevent MI in USA
